Did you know that the Canadian Agency for Drugs and Technologies in Health (CADTH) can now conditionally approve a therapy, rather than offering a definite yes or no?
Here, Don Husereau (Adjunct Professor of Medicine, The University of Ottawa) explains that CADTH are taking this approach when they want to see more evidence for a therapy before signing off on reimbursement, but don't want to delay a treatment that could benefit patients. Offering conditional approval enables CADTH to ensure that innovative treatments are available to patients sooner than in the past, when they would have had to say no while, for example, awaiting further evidence from Phase 3 trials.
So, what does this mean for your market access and HTA strategy? To discuss your evidence base and reimbursement options, arrange a call with our experts via info@mtechaccess.co.uk
This clip was taken from our recent Global Whispers webinar where Don was a guest speaker. The webinar (first broadcast live in March 2024) is now available to watch on demand at: mtechaccess.co.uk/market-acce...
3 июл 2024
